Urinary exosomes are excreted from all nephron segments and may serve as biomarkers for classifying renal diseases. Isolation of urinary exosomes by the established ultracentrifugation method has some limitations for use in a clinical laboratory. We sought a rapid and simple way to obtain urinary exosomes. We used a commercially available nanomembrane concentrator to enrich exosomes from urine by centrifugation at 3,000 g for 10 -30 min. Urinary exosomal markers tumor susceptibility gene 101, aquaporin-2, neuron-specific enolase, annexin V, angiotensinconverting enzyme, and podocalyxin (PODXL) were recovered from the nanomembrane concentrator and detected by Western blotting, and typical features of urinary vesicles were found by electron microscopy. Exosomal markers were detected in as little as 0.5 ml of urine. By the nanomembrane method, exosomal proteins could be recovered from urine samples frozen at Ϫ80°C or refrigerated overnight at 4°C then stored at Ϫ80°C. By enriching exosomes we could detect PODXL, a podocyte marker, which decreased by 71% in five male patients with focal segmental glomerulosclerosis and abundant proteinuria. We conclude that 1) use of a nanomembrane concentrator simplifies and accelerates the enrichment of urinary exosomes; and 2)
NEW URINARY BIOMARKERS WILL likely speed up the development of new treatments for renal diseases (2) . Exosomes containing membrane and cytosolic proteins are shed into the urine from all nephron segments and may be altered in abundance or physical properties in association with various kidney diseases. Pisitkun et al. (5) isolated exosomes from fresh human urine by ultracentrifugation. Our previous studies demonstrated optimal collection, storage, and preservation conditions for exosomes from human urine (7) . Urinary exosomal fetuin-A and Na ϩ /H ϩ exchanger isoform 3 (NHE3) are increased in patients with acute kidney injury (AKI) (1, 6) . Thus urinary exosomes may provide an avenue for the discovery and/or validation of biomarkers for early diagnosis, classification, and monitoring treatment of kidney diseases (4) . However, the ultracentrifugation step limits the assay throughput because of a prolonged 1-2 h of ultracentrifugation and a small number of slots in the rotor. Therefore, we sought an exosome isolation method that would be more suitable for a typical clinical laboratory. Commercially available nanomembrane concentrators are manufactured with a narrow, well-defined molecular pore size distribution, and therefore the molecular size cutoffs are relatively precise. Proteins can be concentrated in excess of 100-fold, soluble protein recoveries can approach 95%, and samples are typically concentrated within 10 -30 min. We evaluated a nanomembrane concentrator with a polyethersulfone membrane and a uniform pore size of 13 nm. The aim of this study was to determine whether nanomembranes can efficiently isolate urinary exosomes with Ͻ100-nm diameter rapidly from human urine and whether this method can be applied to patients with chronic kidney diseases (CKD) with abundant proteinuria.
MATERIALS AND METHODS
Urine collection. All human urine samples were collected and processed as described previously (Institutional Review Board protocol numbers 00-DK-0107 and 06-DK-0020) (7), except that freshly voided spot urine samples (15 ml) from patients with focal segmental glomerulosclerosis (FSGS) were centrifuged at 1,000 g for 10 min and then stored at Ϫ80°C for 1-13 mo/sample until use, and protease inhibitors were added immediately after thawing. Some urine samples from the healthy volunteer were stored at three different conditions: 4°C for 1 h, Ϫ80°C for 1 wk, and refrigerated at 4°C for 24 h and then stored at Ϫ80°C for 1 wk. Urine creatinine was measured by using a creatinine companion kit (Exocell, Philadelphia, PA).
Preparation of urinary exosomes by nanomembrane concentrator. Nanomembrane concentrators (Vivaspin 500, Vivaspin 4, or Vivaspin 20, Sartorius, Goettingen, Germany) were washed to remove glycerol and other preservatives by adding ϳ1 volume of PBS buffer and then centrifuged at 3,000 g at room temperature (RT) before processing of urine samples. After centrifugation of urine samples at 17,000 g at 4°C for 15 min, 0.5, 1.5, or 10 ml of urine supernatant were added to Vivaspin 500, 4, or 20, respectively, nanomembrane concentrator and then centrifuged at 3,000 g at RT for 10 -30 min. Urine proteins were recovered from the nanomembrane concentrator by two methods: 1) a combined retentate (CR) was recovered by adding an equal volume of unheated 2ϫ solubilizing buffer (2ϫ Laemmli buffer with 400 mM DTT) to the retentate while still in the concentrator and shaking at RT for 30 min; or 2) proteins not bound to the nanomembrane and adhering proteins were sequentially recovered. In method 2, the retentate was removed from the concentrator before addition of an equal volume of the preheated (95°C) 2ϫ solubilizing buffer; the nanomembrane was subsequently washed to remove remaining proteins that adhered to the nanomembrane by adding 2 volumes of preheated 1ϫ solubilizing buffer (HSW) into the concentrator and shaking the concentrator at RT for 10 min (Fig. 1) . Urine exosomal proteins isolated by ultracentrifugation (200,000-g pellets) described previously (7) were used as positive controls. The CR method was used to isolate proteins from the urine of 9 patients (5 men and 4 women) with FSGS and 8 normal control volunteers (4 men and 4 women). All of the urinary protein samples were stored at Ϫ80°C until use.
Gel electrophoresis and Western blotting. An equal proportion of the original urine volume was loaded onto gels, except for patients' urine samples, which were first normalized by urine creatinine. The protein samples were analyzed using gel electrophoresis and detected by Coomassie blue staining or Western blotting as described previously (7). Specific antibodies were used in Western blot analysis: tumor susceptibility gene (TSG101), aquaporin-2 (AQP2), neuronspecific enolase (NES) (7), and polyclonal antibodies to angiotensinconverting enzyme (ACE; 1:1,000); and monoclonal antibodies to annexin V (1:250, Abcam, Cambridge, MA) and podocalyxin (PODXL; 1:100, Alpha Diagnostics, San Antonio, TX). The density of the bands was quantified by National Institutes of Health ImageJ software.
Electron microscopy. Exosomal suspensions were mixed 1:1 with 4% paraformaldehyde. This mixture was applied to a 200-mesh nickel grid and washed in 1ϫ PBS solution followed by sterile H2O. The nickel mesh was negatively stained with 0.5% uranyl acetate and visualized using a JEOL 1200 EX electron microscope operated at 60 kV.
Statistical analysis. All data are expressed as means Ϯ SE. Differences between groups were analyzed for statistical significance using a t-test. A P value Ͻ0.05 was accepted as statistically significant.
RESULTS

Isolation of urinary exosomes by nanomembrane concentrator.
To test whether a nanomembrane concentrator can isolate the exosomes from human urine, we compared the efficiency of the nanomembrane concentrator with the standard ultracentrifugation method. Starting with 10 ml of fresh human urine, "fractions" from two recovery protocols (see MATERIALS AND METHODS) were recovered from the concentrator, and five typical urinary exosome markers (TSG101, AQP2, NES, annexin V, and PODXL) were detected by Western blotting. The recovery of TSG101 and AQP2 from the retentate alone was poor, consistent with some exosomes containing these proteins adhering to the nanomembrane. However, the recovery of TSG101 and AQP2 was improved by washing the nanomembrane with heated SDS-containing buffer (HSW). The recovery of NES, annexin V, and PODXL in the CR was the same as by ultracentrifugation. In addition, five exosomal proteins were not detected in the flow-through of the nanomembrane concentrator ( Fig. 2) , indicating that leakage of exosomes or exosome fragments through the device was insignificant.
Electronmicroscopy verified a typical saucer shape with bilayer morphology of urinary vesicles retained by the nanomembrane concentrator (Fig. 3A) . The feature and size distribution were very similar to vesicles isolated using ultracentrifugation (Fig. 3B) .
We determined reproducibility by analyzing a single urine sample in six individual nanomembrane concentrators. TSG101, AQP2, ACE, and PODXL were reproducibly detected with an average coefficient of variation of 7% (Supplementary Fig. 1 ; all supplementary material is available in the online version of this article). Fig. 1 . Isolation of urinary exosomes by a nanomembrane concentrator. Urinary exosomes were isolated from 10-, 1.5-, or 0.5-ml urine samples by the nanomembrane concentrator as described in MATERIALS AND METHODS.
Lower limit of urine sample volume to isolate urinary exosomes by nanomembrane. To determine whether nanomembrane concentrators can be used for small sample volumes typically collected from oliguric patients or stored in clinical archives, we processed 0.5 or 1.5 ml of urine. TSG101, AQP2, and NES were detected by Western blotting from 0.5-or 1.5-ml urine samples (Fig. 4) .
Effect of initial storage conditions on exosome recovery by nanomembrane. We next determined whether nanomembrane concentrators can be used on urine samples that were stored frozen or shipped on ice from a distant clinic to a central analysis laboratory and then stored at Ϫ80°C. We compared the effects of our nanomembrane method on urinary exosomes under three storage conditions (see MATERIALS AND METHODS) after urine collection. We found that four exosomal proteins, namely, TSG101, AQP2, ACE, and PODXL, were detected by Western blotting in each urine sample, whether stored at Ϫ80°C or placed on ice for 24 h and then stored at Ϫ80°C. The recoveries were not significantly different from fresh urine processed within 1 h (Fig. 5) . Total protein patterns were similar in all three conditions (Supplementary Fig. 2) .
Detection of a candidate biomarker in the urine of FSGS patients. To verify whether nanomembrane concentrators could help detect potential biomarkers of urinary exosomal proteins for specific kidney diseases, we isolated exosomal proteins from urine samples from patients with FSGS and normal control volunteers to isolate urinary exosomal proteins. Urinary PODXL, a known apical membrane protein marker for podocytes, decreased significantly from 24 Ϯ 7 to 7 Ϯ 2 density units (P Ͻ 0.05) in male FSGS patients compared with normal, age-matched men. Female FSGS patients also had lower levels of urinary PODXL compared with age-matched female volunteers (29 Ϯ 11 vs. 22 Ϯ 8 density units), but the difference was not statistically significant (Fig. 6) .
DISCUSSION
This study demonstrates that 1) the nanomembrane concentrator can isolate urinary exosomes as effectively as the standard ultracentrifugation method; 2) the nanomembrane concentrator can be used on very small urine samples (0.5 ml); 3) urinary exosomal proteins were stable when they were stored at Ϫ80°C or refrigerated at 4°C for 24 h and then stored at Ϫ80°C; 4) some exosomal proteins adhered to the nanomembrane but could be recovered by washing with heated solubilizing buffer; and 5) nanomembrane concentrators can be used for urine samples from patients despite abundant proteinuria.
Urinary exosomes derive from all cell types that face the urinary space, including glomerular podocytes, renal tubule cells, and cells lining the urinary drainage system (5). A previous study by Pisitkun et al. (5) detected 295 distinct proteins in normal human urinary exosomes, including multi- Fig. 3 . Electron microscopy of urinary vesicles. Urinary vesicles were obtained by nanomembrane concentrator (A) and differential ultracentrifugation (B). Bars, 100 nm. ple proteins associated with renal and systemic diseases. Our recent study verified that fetuin-A increased in urinary exosomes in the early phase of AKI in rats after nephrotoxin injection or ischemia and reperfusion and also increased in intensive care unit patients with AKI (6). du Cheyron et al. (1) reported that urinary membrane-associated NHE3, which was found in urinary exosomes in our previous study (7) , increases in patients with AKI. These findings suggest that urinary exosomes can serve as a source for biomarker discovery to improve early diagnosis, classification, choice of therapeutic approach, and assessment of prognosis for kidney diseases. However, the need for ultracentrifugation, the current method of exosome isolation, limits the application of urinary exosomes in a clinical laboratory. The ultracentrifuge rotor limits the number and volume of urine samples that can be processed, and several hours are needed to process large volumes of urine samples. A rapid, simple method for isolating urinary exosomes is necessary for exosomal markers to be routinely detected in a clinical laboratory.
Exosomes are small internal vesicles (Ͻ100 nm) of multivesicular bodies (MVB) that are delivered to the extracellular fluid by fusion of the outer membrane of MVB with the apical plasma membrane (3, 5) . Exosomes can be isolated from solid-phase components by differential ultracentrifugation based on their very low density. The nanomembrane concentrator is made of the polyethersulfone membrane with a uniform pore size of 13 nm and an ϳ100-kDa molecular mass cut-off. The concentrator is designed with two opposing membranes in a "V-shape" to minimize the effect of shearing forces during centrifugation. We hypothesized that the concentrator should retain the majority of urinary exosomes and allow most of soluble urine proteins (Ͻ100 kDa), such as albumin, globulin, and microglobulin, to pass through the nanomembrane. The concentration procedure can be performed within 30 min using a common tabletop centrifuge. For typical clinical urine samples (Ͻ8 ml), the processing time is almost the same for both nanomembrane concentrator and ultracentrifugation methods. Preparation of exosomes from large-volume urine samples (100 ml, for example) takes 4 h to prepare by ultracentrifugation compared with 30 min using nanomembrane concentrators (assuming the samples are processed with 5 nanomembrane concentrators; then, the retentates are pooled). Using typical rotors, the maximum ultrafiltration rate is 960 ml/h for the nanomembrane concentrator and 96 ml/h by ultracentrifugation. However, the final volume of the concentrated protein can be set by the investigator with the ultracentrifugation method, but it is fixed at ϳ0.2 ml/20 ml nanomembrane concentrator.
We selected several exosome markers including integral membrane proteins (AQP2, ACE, and PODXL), soluble cytoplasmic proteins (NES and annexin V), and a peripheral membrane protein, TSG101. These proteins were detected after concentration from fresh urine samples ranging in size from 0.5 to 10 ml, but also from the urine samples frozen at Ϫ80°C or refrigerated at 4°C for 24 h and then stored at Ϫ80°C. None of the exosomal proteins was detected in the flowthrough fraction, indicating quantitative retention. These findings suggest that nanomembrane concentrators may be used for urinary exosome studies using urine samples with very small volumes (oliguric AKI), small urine aliquots (0.5-1.0 ml) stored at Ϫ80°C, or samples shipped on ice from a distant clinical site.
Some proteins, such as NSE, annexin V, and PODXL, did not adhere to the nanomembrane and were readily recovered. Other exosomal proteins, AQP2 and TSG101, adhered to the nanomembrane, as only a small proportion could be recovered from the retentate. However, we found that using the heated solubilizing buffer more effectively stripped AQP2 and TSG101 from the nanomembrane. We speculate that heterogeneity in the exosome population may account for the effi- Fig. 4 . Isolation of exosomal proteins from a small urine volume by nanomembrane concentrator. Fresh urine samples (0.5 or 1.5 ml) were processed by nanomembrane, proteins were recovered (CR, R, and HSW indicated in Fig. 1) , and Western blots were performed for TSG101, AQP2, and NSE. Lanes 1-3, 0.5 ml of urine; lanes 4 -6, 1.5 ml of urine. Fig. 5 . Effect of storage on urinary exosomal proteins isolated by nanomembrane concentrator. Urine sample from 1 healthy volunteer was processed in 3 storage conditions: within 1 h (lanes 1-3) ; stored at Ϫ80°C (lanes 4 -6) ; and refrigerated at 4°C for 24 h and then stored at Ϫ80°C (lanes 7-9) after collection. Urinary proteins (CR, R, and HSW indicated in Fig. 1) were analyzed by Western blotting of TSG 101, AQP2, angiotensin-converting enzyme (ACE), and PODXL. High-molecular-weight (HMW) and low-molecular-weight (LMW) isoforms of ACE are shown. ciency of extraction from the nanomembrane concentrator. It is also possible that vesicles containing AQP2 and TSG101 have a smaller diameter that can be trapped in the nanomembrane pores during centrifugation. Alternatively, the composition (phosphorylated and/or glycosylated proteins) of some exosome subpopulations may promote adhesion to the nanomembrane. Therefore, isolation conditions must be optimized for maximal recovery of each exosomal protein. Prewashing of the nanomembrane is strongly recommended, as additives such as glycerol increase the variability of exosomal protein recovery (data not shown).
Finally, PODXL, a membrane protein marker for podocytes, was isolated from urine samples of FSGS patients using the nanomembrane concentrator. Exosomal PODXL was decreased significantly in FSGS patients with 2.2-15 g/day of proteinuria. This suggests that nanomembranes can enrich urinary exosomes from the urine samples from CKD with abundant proteinuria, such as diabetic nephropathy, lupus nephritis, and nephritic syndrome, etc.
Conclusion. Urinary exosomes can be rapidly enriched from human urine using a nanomembrane concentrator. This new approach can enrich exosomal proteins from small urine volumes (0.5 ml), samples stored at Ϫ80°C, or samples refrigerated first and then stored at Ϫ80°C. This makes it feasible to store urine samples or ship refrigerated urine from distant clinic sites. Nanomembranes may be useful to more rapidly isolate potential urinary exosomal biomarkers in clinical samples, accelerating the translation of urinary exosomal biomarkers from laboratory bench to clinical laboratory.
